Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 16/20 | 0.56 |
| ▸ | FCER2 | P06734 | 2/20 | 0.56 |
| ▸ | MMP3 | P08254 | 13/20 | 0.52 |
| ▸ | MMP2 | P08253 | 10/20 | 0.52 |
| ▸ | MMP8 | P22894 | 7/20 | 0.52 |
| ▸ | MMP7 | P09237 | 7/20 | 0.52 |
| ▸ | MMP9 | P14780 | 4/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7066963 | 0.87 | MMP1 (0.61) | MMP1FCER2MMP3MMP2MMP8 | |
| SCHEMBL7066966 | 0.87 | MMP1 (0.61) | MMP1FCER2MMP3MMP2MMP8 | |
| SCHEMBL10441159 | 0.86 | ACE (0.59) | — | |
| SCHEMBL989841 | 0.85 | PSMB5 (0.64) | MMP1FCER2MMP3MMP2MMP8 | |
| SCHEMBL15759462 | 0.85 | PSMB5 (0.64) | MMP1FCER2MMP3MMP2MMP8 | |
| SCHEMBL7391831 | 0.82 | MMP1 (0.57) | MMP1FCER2MMP3MMP2MMP8 | |
| SCHEMBL7277442 | 0.82 | MMP1 (0.59) | MMP1FCER2MMP3MMP2MMP8 | |
| SCHEMBL25000564 | 0.81 | MMP1 (0.63) | MMP1FCER2MMP3MMP2MMP8 | |
| SCHEMBL25139508 | 0.81 | MMP1 (0.63) | MMP1FCER2MMP3MMP2MMP8 | |
| SCHEMBL13956893 | 0.81 | MMP1 (0.60) | MMP1FCER2MMP3MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560401-B2 | Method for preparing oligonucleic acid compound | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-24 | — | — | US | disclosed |
| US-20230014840-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-20230018780-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| WO-2021095874-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | 日本新薬株式会社 | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230018780-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | POLRMT, POLR2H, POLM | MMP1 1529/4885FCER2 4881/4885MMP3 2430/4885 |
| US-11560401-B2 | Method for preparing oligonucleic acid compound | POLRMT, POLI, POLR2H | MMP1 2872/4885FCER2 4882/4885MMP3 3939/4885 |
| US-20230014840-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | DNASE1, XRN2, FBL | MMP1 2406/4885FCER2 4675/4885MMP3 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.